Chemogenomics in Drug Discovery
A Medicinal Chemistry Perspective
Methods and Principles in Medicinal Chemistry (Band Nr. 22)

1. Auflage Juli 2004
XXIV, 463 Seiten, Hardcover
227 Abbildungen (44 Farbabbildungen)
15 Tabellen
Handbuch/Nachschlagewerk
Kurzbeschreibung
Die Chemogenomik ist eine Brückendisziplin zwischen Chemie und Biologie, die im Rahmen der Suche nach neuen Wirkstoffen Ansätze der kombinatorischen Chemie mit Proteomik und Genomik verbindet. Zwanzig Forschungsgruppen von Universitäten und aus pharmazeutischen Unternehmen erläutern Ihnen in diesem Band alle Schritte der frühen Wirkstoffforschung - von der Wahl des Targets über Verbindungsbibliotheken bis zum Design von Leitstrukturen. Wirkstoffentwickler und medizinische Chemiker, die mit chemogenomischen Methoden arbeiten, werden auf diese umfangreiche und kompetente Informationsquelle nicht verzichten wollen.
Jetzt kaufen
Preis: 199,00 €
Preis inkl. MwSt, zzgl. Versand
Euro-Preise für Wiley-VCH- und Ernst & Sohn-Titel sind nur für Deutschland gültig. In EU-Ländern gilt die lokale Mehrwertsteuer. Portokosten werden berechnet.
- Gedruckte Ausgabe vergriffen -
Chemogenomics brings together the most powerful concepts in modern chemistry and biology, linking combinatorial chemistry with genomics and proteomics.
This first reference devoted to the topic covers all stages of the early drug discovery process, from target selection to compound library and lead design.
With the combined expertise of 20 research groups from academia and leading pharmaceutical companies, this is a must-have for every drug developer and medicinal chemist applying the powerful methods of chemogenomics to speed up the drug discovery process.
GENERAL ASPECTS
Target Family-directed Masterkeys
Drug Discovery from Side Effects
Chemical Genetics in Drug Discovery
Structural Aspects of Binding Site Similarity
TARGET FAMILIES
Knowledge-based Discovery of Biological Targets
Chemical Kinomics
Kinase Inhibitors
Ion Channel Modulators
Phosphodiesterase Inhibitors
Proteochemometrics
CHEMICAL LIBRARIES
Compound Library and Template Design for GPCRs
Computational Filters in Lead Generation
Ligand-based Design of Focused Libraries
Natural Product-derived Combinatorial Libraries
Combinatorial Chemistry in the Chemical Genomics Age
CHEMBIOCHEM - A European Journal of Chemical Biology
"The contributions in >Chemogenomics in Drug Discovery< are of very high quality and are clearly presented ... All chapters have a high scientific value, and collectively they contribute a great deal to the understanding of how chemogenomics and scaled-up medicinal chemistry can support the early stages of drug discovery. Therefore, this work is highly relevant for everyone with an intereste in modern drug development, and especially for readers in the pharmaceutical industry."
Ulf Börjesson, Institute of Pharmaceutical Chemistry, University of Marburg, Angewandte Chemie, IE, 3rd May Issue 2005-44/19+ Angewandte Chemie, 3. Maiheft 2005-117/19
"... readers hoping to learn about specific aspects will be rewarded with superb writing, good discussions, and excellent examples from current literature."
Steven M. Firestine, Division of Pharmaceutical Sciences, Mylan School of Pharmacy, Duquesne University, Pittsburgh, Journal of Medicinal Chemistry,
Vol. 48, No. 11/2005
"This hallmark text marks a breakthrough in the field...vital to the researcher."
Electric Review, April/May 2005
He is Professor of Pharmaceutical Chemistry at the University of Heidelberg, former Chair of The QSAR and Modelling Society, and IUPAC Fellow. From his scientific work resulted five books on QSAR, 3D QSAR, and Drug
Design (the German book "Wirkstoffdesign" received the 1999 Book Award of the FCI, Association of Chemical Industry) and about 90 publications.
He is a member of several Scientific Advisory Boards, coeditor of the Wiley-VCH book series "Methods and Principles in Medicinal Chemistry", and member of the Editorial Boards of several scientific journals.
Gerhard Müller graduated in Organic Chemistry from the University of Frankfurt/Main (Germany) and received his PhD in 1992 at the Technical University of Munich. After two years in the Medicinal Chemistry department of Glaxo Verona (Italy), he joined the central research facility of the Bayer AG, Leverkusen. From 1998 onwards he was project manager of a target family approach in medicinal chemistry. From 2001 to 2003 he headed the chemistry section of Organon's Lead Discovery Unit in Oss (The Netherlands). Since summer 2003, Gerhard Müller is the chief scientific officer of the Munich-based biotech company Axxima Pharmaceuticals AG.